ArticleBlood cell therapy2025
Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants.
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral reactivations frequently complicate unrelated donor (UD) and haploidentical (HI) stem cell transplants (SCTs). We analyzed incidence, risk factors, and outcomes of viral reactivations in alternative donor transplants at our center. Methods: This retrospective study included all cases of UD or HI transplants performed between January 1, 2009 and February 29, 2020. We identified 196 viral reactivations in 87 patients in this cohort. Results: The incidence of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) reactivation was 80.5, 36.7, and 26%, respectively. CMV colitis was observed in six patients (8.5%). Acute graft-versus-host disease (GVHD) was a significant risk factor for CMV reactivation. Four patients (5%) developed ADV disease requiring treatment with cidofovir. Anti-thymocyte globulin use and acute GVHD were significant risk factors for ADV reactivation. Mild hemorrhagic cystitis due to BK virus was observed in 32% patients. However, significant cystitis requiring intervention was seen in only four patients. Two patients developed EBV-related lymphoproliferative disorder and one patient experienced human herpes virus 6-related graft failure. Viral reactivations had no impact on overall survival. Conclusions: The incidence of CMV reactivation in alternative donor HSCTs is high (80%) in the Indian population. Acute GVHD is a significant risk factor for CMV, ADV, or EBV reactivation. The rates of ADV, BK virus, and EBV reactivation requiring intervention are low. Better prophylactic strategies are required to prevent CMV reactivation in alternative donor transplants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.